MedImmune's FluMist backed for babies

Published: May 16, 2007 at 5:16 PM

GAITHERSBURG, Md., May 16 (UPI) -- An advisory panel to the U.S. Food and Drug Administration Wednesday backed the use of MedImmune's FluMist for children ages 2 years and older.

The Vaccines and Related Biological Products Advisory Committee voted that the FDA should expand the product's labeling to allow use of the intranasal treatment in this pediatric population, although MedImmune is seeking approval for FluMist in children as young as 1 who do not have a history of asthma or wheezing.

Members of the expert panel said they were persuaded by the data that FluMist is effective in children ages 6 months or older and safe for children 2 years and older.

The FDA is not bound to follow the advice of its panels, but does so in most cases.

FluMist is currently approved for use in patients 5 to 49 years. MedImmune is being acquired by AstraZeneca.

© 2007 United Press International, Inc. All Rights Reserved.
Order reprints



Additional News Stories
Distracted man drives Bugatti into lagoon (10 min)
COL FB: Rutgers 31, South Florida 0 (14 min)
Tagliabue to head a study of USOC (20 min)
NFL: San Francisco 10, Chicago 6 (25 min)
NBA: Cleveland 109, Miami 102 (43 min)
UPI Sports Calendar for Friday, Nov. 13 (48 min)
NHL: Nashville 3, St. Louis 1
fark
Drew's list of 'seasonal' stories is woefully incomplete without "annual turkey baster search"
Experts wonder if the upswing in retail theft may be connected to the unemployment rate. What the...
MPAA shuts down an entire town's wi-fi because one person illegally downloaded a movie. Take that,...
Verizon has found a way to charge you for accidental keystrokes
Coming to a hipster douche near you: 1890s fashion. 'Cause nothing says "manly" like knee socks,...
Tennessee man found asleep in a ditch with a loaded rifle and a bottle of moonshine